Abstract
Glioblastoma (glioblastoma multiforme; GBM; WHO Grade IV) accounts for the majority of primary malignant brain tumors in adults. Amplification and mutation of the epidermal growth factor receptor (EGFR) gene represent signature genetic abnormalities encountered in GBM. A range of potential therapies that target EGFR or its mutant constitutively active form, ΔEGFR, including tyrosine kinase inhibitors (TKIs), monoclonal antibodies, vaccines, and RNA-based agents, are currently in development or in clinical trials for the treatment of GBM. Data from experimental studies evaluating these therapies have been very promising; however, their efficacy in the clinic has so far been limited by both upfront and acquired drug resistance. This review discusses the current status of anti-EGFR agents and the recurrent problem of resistance to these agents that strongly indicates that a multiple target approach will provide a more favorable future for these types of targeted therapies in GBM.
Keywords: Epidermal growth factor receptor, EGFR-targeted therapy, Glioblastoma, therapeutic resistance, carmustine, cluster of differentiation, adenosine triphosphate, cyclodextrin-modified dendritic polyamine complexes, Glioblastoma multiforme, janus kinase, non small cell lung carcinoma, mammalian target of rapamycin, receptor tyrosine kinases, temozolomide, urokinase plasminogen activator receptor
Current Cancer Drug Targets
Title: Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance
Volume: 12 Issue: 3
Author(s): T. E. Taylor, F. B. Furnari and W. K. Cavenee
Affiliation:
Keywords: Epidermal growth factor receptor, EGFR-targeted therapy, Glioblastoma, therapeutic resistance, carmustine, cluster of differentiation, adenosine triphosphate, cyclodextrin-modified dendritic polyamine complexes, Glioblastoma multiforme, janus kinase, non small cell lung carcinoma, mammalian target of rapamycin, receptor tyrosine kinases, temozolomide, urokinase plasminogen activator receptor
Abstract: Glioblastoma (glioblastoma multiforme; GBM; WHO Grade IV) accounts for the majority of primary malignant brain tumors in adults. Amplification and mutation of the epidermal growth factor receptor (EGFR) gene represent signature genetic abnormalities encountered in GBM. A range of potential therapies that target EGFR or its mutant constitutively active form, ΔEGFR, including tyrosine kinase inhibitors (TKIs), monoclonal antibodies, vaccines, and RNA-based agents, are currently in development or in clinical trials for the treatment of GBM. Data from experimental studies evaluating these therapies have been very promising; however, their efficacy in the clinic has so far been limited by both upfront and acquired drug resistance. This review discusses the current status of anti-EGFR agents and the recurrent problem of resistance to these agents that strongly indicates that a multiple target approach will provide a more favorable future for these types of targeted therapies in GBM.
Export Options
About this article
Cite this article as:
E. Taylor T., B. Furnari F. and K. Cavenee W., Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance, Current Cancer Drug Targets 2012; 12 (3) . https://dx.doi.org/10.2174/156800912799277557
DOI https://dx.doi.org/10.2174/156800912799277557 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ferroptosis Inducers for Prostate Cancer Therapy
Current Medicinal Chemistry MiR-125b Inhibits Cell Proliferation and Induces Apoptosis in Human Colon Cancer SW480 Cells <i>via</i> Targeting STAT3
Recent Patents on Anti-Cancer Drug Discovery Targeting Blood Vessels for the Treatment of Non-Small Cell Lung Cancer
Current Cancer Drug Targets Intracellular Drug Delivery: Mechanisms for Cell Entry
Current Pharmaceutical Design Recent Software Developments and Applications in Functional Imaging
Current Pharmaceutical Biotechnology Meet Our Co-Editor
Current Signal Transduction Therapy The Role of 18 kDa Mitochondrial Translocator Protein (TSPO) in Programmed Cell Death, and Effects of Steroids on TSPO Expression
Current Molecular Medicine Juglone Exerts Cytotoxic, Anti-proliferative and Anti-invasive Effects on Glioblastoma Multiforme in a Cell Culture Model
Anti-Cancer Agents in Medicinal Chemistry Oncolytic Virus Therapy - Foreword
Current Cancer Drug Targets ABC Transporters as Potential Targets for Modulation of Drug Resistance
Mini-Reviews in Medicinal Chemistry Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases
Current Signal Transduction Therapy Near-infrared Light Activatable Multimodal Gold Nanostructures Platform: An Emerging Paradigm for Cancer Therapy
Current Cancer Drug Targets Lipid Nanoparticles to Deliver miRNA in Cancer
Current Pharmaceutical Biotechnology Addressing the Challenge: Current and Future Directions in Ovarian Cancer Therapy
Current Gene Therapy Passive Targeting of Cyclophosphamide-Loaded Carbonate Apatite Nanoparticles to Liver Impedes Breast Tumor Growth in a Syngeneic Model
Current Pharmaceutical Design Gold Nanostructures as Photothermal Therapy Agent for Cancer
Anti-Cancer Agents in Medicinal Chemistry Tapasin and Human Leukocyte Antigen Class I Dysregulation Correlates with Survival in Glioblastoma Multiforme
Anti-Cancer Agents in Medicinal Chemistry PET and SPECT Imaging for the Acceleration of Anti-Cancer Drug Development
Current Drug Targets 2D, 3D, G-QSAR and Docking Studies of Thiazolyl-pyrazoline Analogues as Potent (Epidermal Growth Factor Receptor-tyrosine Kinase) EGFR-TK Inhibitors
Letters in Drug Design & Discovery Targeting βIII-Tubulin in Glioblastoma Multiforme: From Cell Biology and Histopathology to Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry